{"abstract": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "web_url": "https://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html", "snippet": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "lead_paragraph": "Johnson & Johnson has agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the antipsychotic drug Risperdal to older adults, children and people with developmental disabilities, the Justice Department said on Monday. ", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-articleLarge.jpg", "height": 392, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2013/11/05/business/Drug2/Drug2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 392}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-jumbo.jpg", "height": 669, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-superJumbo.jpg", "height": 1339, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2013/11/05/business/Drug2/Drug2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "J.&J. to Pay $2.2 Billion in Risperdal Settlement", "kicker": null, "content_kicker": null, "print_headline": "J.&J. to Pay $2.2 Billion In Risperdal Settlement", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Johnson & Johnson", "rank": 1, "major": "N"}, {"name": "persons", "value": "Thomas, Katie", "rank": 2, "major": "N"}, {"name": "subject", "value": "Fines (Penalties)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "subject", "value": "ADVERTISING AND MARKETING", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mental Health and Disorders", "rank": 6, "major": "N"}], "pub_date": "2013-11-04T17:26:12+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Katie Thomas", "person": [{"firstname": "Katie", "middlename": null, "lastname": "Thomas", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/5c86401d-cb0c-52ea-ba9b-ec51b61c2f6e", "word_count": 1113, "uri": "nyt://article/5c86401d-cb0c-52ea-ba9b-ec51b61c2f6e"}